CANATU

Annual General Meeting

Varsinainen yhtiökokous

May 15, 2025

3:00 p.m. EEST

Event Studio Eliel

1. Opening of the meeting

1. Kokouksen avaaminen

CANATU

2. Calling the meeting to order

2. Kokouksen järjestäytyminen

CANATU

Agenda

1. Opening of the meeting / *Kokouksen avaaminen*
2. Calling the meeting to order / *Kokouksen järjestäytyminen*
3. Election of persons to scrutinize the minutes and supervise thecounting of votes / *Pöytäkirjantarkastajien ja ääntenlaskun valvojien valitseminen*
4. Recording the legality of the meeting / *Kokouksen laillisuuden toteaminen*
5. Recording the attendance at the meeting and adoption of the list of votes / *Läsnä olevien toteaminen ja ääniluettelon vahvistaminen*
6. Presentation of the Financial Statements, also including the Consolidated Financial Statements, the Report by the Board of Directors and the Auditor's Report for the year 2024 / *Vuoden 2024 tilinpäätöksen, johon sisältyy myös konsernitilinpäätös, toimintakertomuksen ja tilintarkastuskertomuksen esittäminen*
7. Adoption of the Financial Statements, which also includes the adoption of the Consolidated Financial Statements / *Tilinpäätöksen vahvistaminen, joka käsittää myös konsernitilinpäätöksen vahvistamisen*
8. Resolution on the use of the profit shown on the balance sheet and the distribution of dividend / *Taseen osoittaman voiton käyttäminen ja osingonjaosta päättäminen*
9. Resolution on the discharge of the members of the Board of Directors and the CEO from liability for the financial period 1 January – 31 December 2024 / *Vastuuvapaudesta päättäminen hallituksen jäsenille ja toimitusjohtajalle tilikaudelta 1.1.31.12.2024*
10. Resolution on the remuneration of the members of the Board of Directors / *Hallituksen jäsenten palkkioista päättäminen*
11. Resolution on the number of members of the Board of Directors / *Hallituksen jäsenten lukumäärästä päättäminen*
12. Election of the members of the Board of Directors / *Hallituksen jäsenten valitseminen*
13. Resolution on the remuneration of the auditor / *Tilintarkastajan palkkiosta päättäminen*
14. Election of the auditor / *Tilintarkastajan valitseminen*
15. Authorizing the Board of Directors to resolve on the repurchase of the company's own shares / *Hallituksen valtuuttaminen päättämään omien osakkeiden hankkimisesta*
16. Authorizing the Board of Directors to resolve on the issuance of shares and special rights entitling to shares / *Hallituksen valtuuttaminen päättämään osakkeiden ja osakkeisiin oikeuttavien erityisten oikeuksien antamisesta*
17. Closing of the meeting / *Kokouksen päättäminen*

CANATU

3. Election of persons to scrutinize the minutes and supervise the counting of votes

3. Pöytäkirjantarkas-tajien ja ääntenlaskun valvojien valitseminen

CANATU

4. Recording the legality of the meeting

4. Kokouksen laillisuuden toteaminen

CANATU

5. Recording the attendance at the meeting and adoption of the list of votes

5. Läsnä olevien toteaminen ja ääniluettelon vahvistaminen

CANATU

6. Presentation of the Financial Statements, also including the Consolidated Financial Statements, the Report by the Board of Directors and the Auditor's Report for the year 2024

6. Vuoden 2024 tilinpäätöksen, johon sisältyy myös konsernitilinpäätös, toimintakertomuksen ja tilintarkastuskertomuksen esittäminen

CANATU

https://live2.syncwords.com/d-f6yFqm

Advanced carbon nanotubes enabling AI growth

Juha Kokkonen

CEO, Canatu Plc

CANATU

Cutting-edge nano carbon deep tech for the industry leading customers

- Listed on the Nasdaq First North Growth Market in September 2024
- Differentiated, IPR-protected Dry Deposition™ CNT technology
- Customer relationships with global industry leaders
- Proven mass production for Automotive since 2015 and Semiconductor since 2021
- 137 employees representing 35 nationalities



CANATU

Canatu's current high-growth markets are undergoing transformation

Semiconductor

~90%

of 2024 revenue

Semiconductor is experiencing growing demand for advanced chips due to advancements in AI and computing, with sub-7 nm chips made by EUV technology growing the fastest.

Automotive



~10%

of 2024 revenue

Automotive is seeking to shift into assisted and autonomous driving and EVs.

Medical diagnostics

Medical diagnostics aims to increasingly transition to point-of-care from laboratory-based testing in some parts of the care chain.

CANATU

Canatu's asset-light business model enables scalability

CNT product sales

Semiconductor products

in mass production since 2021

Automotive products

in mass production since 2015, ~1,1 M sensors delivered, 0 field returns

Medical diagnostics

under development

CNT reactor sales

Non-recurring revenue

from reactor sales and technology licensing

Recurring revenue

from consumables and royalty payments from each product sold

First reactor shipments

to customers in 2024, used for CNT pellicle membrane production

Highlights 2024

Publicly listing on Nasdaq First North GM

Canatu was listed on the Nasdaq First North Growth Market Finland on 17 September 2024 through the combination with Lifeline SPAC I.



Sustaining strong top-line growth

We sustained strong top-line growth, delivering revenue of 22.0M€ (13.6). The revenue growth supported a strong gross profit which grew by 43.1% to EUR 13.8 (9.6) million, representing 62.5% of revenue.



Shipping first CNT100 SEMI reactors

We shipped our first two CNT100 SEMI reactors to global semiconductor customers for CNT pellicle membrane production.



Leadership in inspection membranes

We continued solidifying our position as a leading supplier of inspection membranes for patterned EUV mask inspection.



Advancing R&D and IPR

Canatu continued strong investments in R&D, CAPEX, and IPR, resulting in 13 new patents. Key investments were focused on the new fully automated production line and ISO3 cleanroom.



Attracting top talent

We expanded our workforce, growing full-time employees to 123 (93) in 2024, with a total headcount of 137 (109) at the year-end.

2024 key figures (unaudited pro forma)

REVENUE M€



REVENUE BY BUSINESS UNIT %



REVENUE GROWTH

62.1%

(62.1%)

GROSS PROFIT

13.8M€

(9.6M€)

GROSS MARGIN

62.5%

(70.9%)

ADJUSTED EBIT MARGIN

-21.9%

(-10.0%)

CAPEX

5.0M€

(4.7M€)

PATENTS & APPLICATIONS

213

(192)

EMPLOYEES (FTE)

123

(93)

CANATU

Consolidated income statement and balance sheet

Income statement – key line items

M€	Consolidated 1 Jan – 31 Dec 2024	Pro forma 1 Jan – 31 Dec 2024
Revenue	3.3	22.0
Operating profit (loss)	-5.2	-5.3
Profit (loss) for the financial period	-3.6	-1.7
Earnings per share (€)	-0.20	-0.05

Balance sheet – key line items

M€	Consolidated 31 Dec 2024
Non-current assets	18.7
Current assets	106.7
of which cash & cash equivalents	*97.9*
TOTAL ASSETS	125.4
Equity	113.5
Non-current liabilities	4.4
Current liabilities	7.5
TOTAL EQUITY & LIABILITIES	125.4

Parent company income statement and balance sheet

Income statement – key line items

M€	Canatu Plc 1 Jan – 31 Dec 2024
Revenue	0.1
Operating profit (loss)	-1.5
Profit (loss) for the financial period	0.2

Balance sheet – key line items

M€	Canatu Plc 31 Dec 2024
Non-current assets	21.4
Current assets	96.7
of which cash & cash equivalents	*96.1*
TOTAL ASSETS	118.0
Equity	117.3
Non-current liabilities	-
Current liabilities	0.7
TOTAL EQUITY & LIABILITIES	118.0

Long-term financial targets for 2027

Canatu's long-term financial targets are:

- Revenue over EUR 100 M€
- EBIT margin (adjusted for goodwill amortization under Finnish Accounting Standards) over 30%

Relative contribution:

- Semiconductor: Large
- Automotive: Medium
- Medical diagnostics: Limited

- CAPEX: avg. 5-6M€/year
- Hiring: 25-35 FTEs/year



CANATU

Summary

1. Rapidly growing deep technology company with attractive margins
2. Current, high-growth focus markets are estimated to grow to EUR 2–4 billion by 2030
3. Customer relationships with leading global companies
4. Differentiated IPR-protected technology supporting a strong competitive position
5. Proven and efficient mass manufacturing capability
6. Business model enabling scalable, asset-light growth with high-margin potential
7. Technological expertise with experienced management attracting global talent

= Financial targets of annual revenue of over EUR 100 million and adjusted EBIT margin[1)] of over 30% in 2027

CANATU

1) Adjusted for goodwill amortisations under the Finnish Accounting Standards

Auditor’s report

Jussi Paski
Authorised Public Accountant, KHT
KPMG Oy Ab

Financial statements 31 December, 2024
Auditors report 28 March, 2025

KPMG

Opinion

- In our opinion, the financial statements give a true and fair view of the group's and the company's financial performance and financial position in accordance with the laws and regulations governing the preparation of financial statements in Finland and comply with statutory requirements.

CANATU

7. Adoption of the Financial Statements, which also includes the adoption of the Consolidated Financial Statements

7. Tilinpäätöksen vahvistaminen, joka käsittää myös konsernitilinpäätöksen vahvistamisen

CANATU

8. Resolution on the use of the profit shown on the balance sheet and the distribution of dividend

8. Taseen osoittaman voiton käyttäminen ja osingonjaosta päättäminen

The Board of Directors proposes to the AGM that no dividend be distributed for the financial period ended on 31 December 2024 and that the result for the financial period be recorded in the retained earnings account.

9. Resolution on the discharge of the members of the Board of Directors and the CEO from liability for the financial period 1 January – 31 December 2024

9. Vastuuvapaudesta päättäminen hallituksen jäsenille ja toimitusjohtajalle tilikaudelta 1.1.–31.12.2024

CANATU

10. Resolution on the remuneration of the members of the Board of Directors

10. Hallituksen jäsenten palkkioista päättäminen

CANATU

10. Resolution on the remuneration of the members of the Board of Directors

- The Nomination Board proposes that the members of the Board of Directors be paid annual remuneration as follows:
  - EUR 80,000 for the Chair of the Board; and
  - EUR 60,000 for each ordinary member of the Board.

- The annual remuneration will be paid to the Board members in proportion to the length of their term, so that for each month commencing until the next Annual General Meeting, an amount equal to the annual remuneration divided by twelve (12) shall accrue.

- Further, the Nomination Board proposes that the travel expenses and other costs of the members of the Board of Directors directly related to board work are paid in accordance with the company's policy in force from time to time and that each member of the Board of Directors is paid a separate travel fee of EUR 1,000 in addition to travel expenses for meetings held outside their country of residence.

11. Resolution on the number of members of the Board of Directors

11. Hallituksen jäsenten lukumäärästä päättäminen

The Nomination Board proposes that the number of members of the Board of Directors shall be eight.

CANATU

12. Election of the members of the Board of Directors

12. Hallituksen jäsenten valitseminen

CANATU

13. Resolution on the remuneration of the auditor

13. Tilintarkastajan palkkiosta päättäminen

The Board of Directors proposes to the AGM that the auditor's remuneration be paid in accordance with a reasonable invoice approved by the company.

CANATU

14. Election of the auditor

14. Tilintarkastajan valitseminen

The Board of Directors proposes to the AGM that Authorized Public Accounting firm KPMG Oy Ab be re-elected as the company's auditor until the closing of the next AGM.

KPMG Oy Ab has informed that, should it be elected as the company's auditor, Authorized Public Accountant Jussi Paski will act as the principal auditor.

15. Authorizing the Board of Directors to resolve on the repurchase of the company's own shares

15. Hallituksen valtuuttaminen päättämään omien osakkeiden hankkimisesta

CANATU

15. Authorizing the Board of Directors to resolve on the repurchase of the company's own shares

- The Board of Directors proposes to the AGM that the Board of Directors be authorized to resolve on the repurchase of a maximum of 2,225,428 series A shares in one or several installments.
- The price paid for the shares must be based on the price of the company's share on the multilateral trading facility such that the minimum price of any repurchased shares is the lowest market price of the share quoted on the multilateral trading facility during the term of validity of the authorization and the maximum price, correspondingly, the highest market price quoted on the multilateral trading facility during the term of validity of the authorization.
- The authorization can be used to develop the company's capital structure, finance or execute corporate acquisitions or other arrangements, implement incentive schemes for the management or key employees, or shares may be repurchased based on it to be otherwise transferred, cancelled or held by the company. The Board of Directors is authorized to decide on all other matters relating to the repurchase of the company's own shares, including the right to decide on repurchase otherwise than in proportion to the shares held by the shareholders.
- The authorization is proposed to remain valid until the closing of the next AGM, however no longer than until 30 June 2026.

16. Authorizing the Board of Directors to resolve on the issuance of shares and special rights entitling to shares

16. Hallituksen valtuuttaminen päättämään osakkeiden ja osakkeisiin oikeuttavien erityisten oikeuksien antamisesta

CANATU

16. Authorizing the Board of Directors to resolve on the issuance of shares and special rights entitling to shares

- The Board of Directors proposes to the AGM that the Board of Directors be authorized to resolve to issue in total a maximum of 2,225,428 series A shares through issuance of series A shares or special rights entitling to series A shares under Chapter 10, Section 1 of the Finnish Companies Act in one or several installments, against or without payment. Based on the authorization, either new shares or treasury shares held by the company may be issued.
- The authorization can be used to develop the company's capital structure, widen the ownership base, finance or execute corporate acquisitions or other arrangements, implement incentive schemes for the management or key employees or for other purposes resolved by the Board of Directors. The Board of Directors is authorized to decide on all other matters relating to the issuance of shares and special rights entitling to shares, including the right to deviate from the shareholders' pre-emptive rights.
- The authorization is proposed to remain valid until the closing of the next AGM, however no longer than until 30 June 2026.

17. Closing of the meeting

17. Kokouksen päättäminen

CANATU

Thank you
for your participation!

Next events:

Aug 29, 2025: Half-Year Report

CANATU

Disclaimer

Notice

Canatu Plc (the "Company") has prepared this presentation for information purposes only. For the purposes of this disclaimer, "presentation" means these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during the presentation meeting.

The information contained in this presentation is not for publication or distribution, directly or indirectly, in or into the United States, Canada, New Zealand, Australia, Japan, Hong Kong, Singapore, South Africa or any other jurisdiction where such publication or distribution would violate applicable laws or rules or would require additional documents to be completed or registered or require any measure to be undertaken in addition to the requirements under Finnish law. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. The information contained in this presentation does not constitute an offer of securities for sale in the United States, nor may the securities be offered or sold in the United States absent registration or an exemption from registration as provided in the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder. The Company does not intend to register any shares or other securities in the United States or to conduct a public offering of securities in the United States.

This presentation does not constitute an offer of or an invitation by or on behalf of, the Company, or any other person, to issue, subscribe for, purchase or sell any securities. This presentation does not constitute a listing prospectus or a company description. You should consult the company description, prepared in accordance with the decree of the Ministry of Finance (1281/2018, as amended) on the basic information document referred to in Chapter 3, Section 2 of the Securities Markets Act (746/2012, as amended), the Nasdaq First North Growth Market Rulebook for Issuers of Shares, and other applicable regulations, and any subsequent information published by the Company for more complete information about the Company and its securities. No part of this presentation, nor the fact of its distribution, should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

This presentation contains financial information regarding the business and assets of the Company. Such financial information may not have been audited, reviewed or verified by any independent accounting firm. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. The Company, nor any of its respective affiliates, advisors or representatives or any other person, shall have any liability whatsoever (in negligence or otherwise) for any loss however arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. Each person must rely on their own examination and analysis of the Company and its securities, including the merits and risks involved.

Carnegie Investment Bank AB (publ) acts as the Company's certified advisor.

Forward-looking statements

Certain statements in this presentation are "forward-looking statements". Forward-looking statements include statements concerning plans, assumptions, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans or intentions relating to acquisitions, the Company's competitive strengths and weaknesses, plans or goals relating to financial position, future operations and development, its business strategy and the anticipated trends in the industry and the political and legal environment in which it operates and other information that is not historical information, such as revenue growth, EBIT growth, cost savings, investments, future cash flow generation, operating profit margin, operating capital expenditure, ratio of net debt and EBIT, revenue, and operating results. In some instances, they can be identified by the use of forward-looking terminology, including the terms "believes", "intends", "may", "will" or "should" or, in each case, their negative or variations on comparable terminology.

Forward-looking statements in this presentation are based on various assumptions, many of which in turn are based on assumptions. By their very nature, forward-looking statements involve inherent risks, uncertainties and assumptions, both general and specific, and the risk exists that the predictions, forecasts, projections, plans and other forward-looking statements will not be achieved. Given these risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements. Any information, views and forward-looking statements contained in this presentation speak only as at the date of this presentation. Save as required by law, the Company or Carnegie Investment Bank AB (publ) do not intend and do not assume any obligation to update or correct any forward-looking statement contained in this presentation and do not undertake to publish such updates or corrections.